Navigation Links
Intellect Neurosciences, Inc. to Present Data on Alzheimer's Vaccine at 13th International Congress of Immunology Conference
Date:8/20/2007

Chimeric Peptide Vaccine Aims to Use Memory Imprint to Yield a Strong and

Highly Specific Immune Response

NEW YORK, Aug. 20 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS) a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders, announced today that Dr. Rachel Eren, Vice President Research, will present new data regarding the Company's RECALL-VAX(TM) chimeric peptide vaccine technology at the 13th International Congress of Immunology on Thursday, August 23, 2007 in Rio de Janeiro, Brazil. Mice immunized with RECALL-VAX(TM) constructs mounted a robust and highly specific immune response against beta-amyloid. The data demonstrate for the first time that a "free-end specific" polyclonal response to beta-amyloid can be achieved, potentially overcoming an important safety concern for active immunization of Alzheimer's disease patients.

"We are pleased with our scientists' progress in establishing important proof of principle for this novel and proprietary vaccine technology, which is designed to make active immunization safe and practical for treating Alzheimer's patients," commented Dr. Daniel Chain, Intellect's Chairman and CEO. He added: "We believe that RECALL-VAX(TM) could potentially be used prophylactically to prevent or delay the onset of Alzheimer's disease in elderly people."

"There are multiple challenges in developing a means to safely immunize elderly individuals and avoid the failures encountered in previous clinical trials sponsored by major pharmaceutical companies," commented Professor Benjamin Chain at the Department of Immunology and Molecular Pathology, Windeyer Institute of Medical Sciences, University College London. Professor Chain added: "The major challenges are the need to: (i) mount a robust immune response when the immune system has become senescent as
'/>"/>

SOURCE Intellect Neurosciences, Inc.

Copyright©2007 PR Newswire.

1

GOOD

Page: 1 2 3

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...linker.comannouncesthatanewmarketresearchreportisa...es-AWorldMarketReview ,, http://www.reportli...-Market-Review.html#utm_source=prnewswire&utm_...obalgeneralanesthesiadisposablesmarketischaracteri...erisewitnessedingeneralsurgicalprocedures,growingp...
(Date:11/23/2009)...l/-- CryoLife,Inc. (NYSE: CRY ),animplantablebiolo...gcompany,announcedtodaythatitisscheduledtoparticip...nferenceatTheNewYorkPalaceHotelonDecember1,2009. ,...ficerofCryoLife,Inc.,willprovideacorporateoverview...tionandanswersessionat4:30p.m.EasternTime. ,, C...
(Date:11/23/2009)...e/--Sarnova,Inc.,thenation,sleadingspecialtydistri...ices(EMS)andrespiratorymarkets,announcedtodaythati...am.ThenewexecutivesincludeTomDavid,executivevicepr...generalcounsel;SteveLacke,executivevicepresidentof...ofcorporatedevelopment. ,, "Ihaveworkedwithallo...
Breaking Medicine Technology:Reportlinker Adds Anesthesia Disposables - A World Market Review 2Reportlinker Adds Anesthesia Disposables - A World Market Review 3Reportlinker Adds Anesthesia Disposables - A World Market Review 4Reportlinker Adds Anesthesia Disposables - A World Market Review 5Reportlinker Adds Anesthesia Disposables - A World Market Review 6CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference 2Sarnova Expands Senior Management Team 231 Breast Cancer Myths 26amp 3B Truths in 31 Days 58811 131 Breast Cancer Myths 26amp 3B Truths in 31 Days 58811 2Senate Committee Addresses Some Issues On Affordability Fails To Correct Abortion Problems And Immigration Concerns Say USCCB Officials 58808 1Senate Committee Addresses Some Issues On Affordability Fails To Correct Abortion Problems And Immigration Concerns Say USCCB Officials 58808 2You Can Thrive 21 Burlesque Show Celebrates the Girls and the Women Who Are Battling to Keep Them 58805 1You Can Thrive 21 Burlesque Show Celebrates the Girls and the Women Who Are Battling to Keep Them 58805 2
...gical Therapeutics, Inc.,announced today the comme...trolled, multinational study of LT-NS001, a novel ...naproxen, a non-steroidal,anti-inflammatory drug (...en worldwide for the treatment of pain, inflammati... arthritis (RA) and osteoarthritis,(OA)., "Despit...
...otope Based Delivery System Has Potential to, Help...arities Reported at AS... experience with the,FDA cleared Axxent(R) Electro...tes that the X-Ray-based, non-isotopic treatment i...tage breast cancer. Initial data,from this multi-c...
Other Medicine Technology:Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001 2Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium 2Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium 3Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium 4
(Date:11/24/2009)... NCL Security Launches EyeCentral Remote Video Pla...ing Monthly Revenue for Central Stations and Secur...xas (PRWEB) November 24, 2009 -- NCL Security Laun...rity Industry to Generate Recurring Monthly Revenu...quot;Integrated security systems has been and stil...
(Date:11/24/2009).../PRNewswire-USNewswire/--Newpeer-revieweddatafindi...nsinfectedwithchronichepatitisCvirushavereceivedan...atCongressneedstomoveurgentlyonbipartisanlegislati...veillanceefforts,the NationalViralHepatitisRoundta...congressionalaction,millionsofAmericansinfectedwit...
(Date:11/23/2009)...iversity of Michigan determined that only 663,000 ...patitis C virus (HCV) infection received antiviral...ppear to be declining, in part because only half o...sturbing trend continues, by 2030 less than 15% of...y antiviral therapy. This study, the first to ana...
(Date:11/23/2009),, NEWYORK,Nov.23/PRNewswire/--Livingwithchronicpaincanbedifficult-andthestressoftheholidayseasoncanprovetobequitechallengingforthoselivingwithpain. ,, ListentothisreportfromPfizerInc.at: ,
(Date:11/23/2009)...the hook for the high cost of drug advertising tha...tudy led by a University of British Columbia healt...ay in the Archives of Internal Medicine , examine...ing drug also known by the trade name Plavix used ...e. The drug was selected to study the impact of ad...
Breaking Medicine News(10 mins):Health News:NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers 2Health News:NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington 2Health News:Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US 2Health News:Drug ads ineffective for boosting sales, could cost taxpayers: UBC-Harvard study 2
...ems, Inc.,(NYSE: DST ) will release its financial...08, on Tuesday, July 22, 2008, after the close of ...any will host a conference call on Wednesday, July...rnational,callers, the dial-in number is (612) 234...
...iming June,20 Donated Dental Services (DDS) Progra...l acknowledged the significant charitable contribu...) members across the state., "We are extremely pl...he inception of the Pennsylvania DDS,program in 19...
... immune system , , TUESDAY, June 24 (Healt...etastatic colon cancer appears to work in mice, r...operty: It acts on the immune system in the intes...one and one in the gut," said lead researcher Dr. ...
... Protect Patient Access To Community,Pharmacies, ...entatives voted 355 to 59 in favor of H.R. 6331, w...care bill contains three critical,provisions for c...ment that would have driven thousands of,community...
...bare metal devices, study suggests , , TUE...ho got drug-coated stents did better than those wh...tudy found. , But it isn,t a simple either-or issu... October 2002 and March 2003, when only bare-metal...
...ordering supplies has helped Geisinger cut $30 mil...rs, made it easier to recall medications in the ev...uplication of many products. , Geisinger,s Supp...ovation Award from the Premier healthcare alliance...
Other Medicine News:Health News:DST Systems, Inc. Announces Notification of Earnings Release Date 2Health News:Governor Lauds Pennsylvania Dental Association Member Participation in Donated Dental Services Program 2Health News:Vaccine Stops Colon Cancer's Spread in Mice 2Health News:Drug-Coated Stents Reduce Repeat Artery Procedures 2Health News:Drug-Coated Stents Reduce Repeat Artery Procedures 3Health News:Geisinger saves millions in medical dollars through better supply management 2
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...
Medicine Products: